

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Graham
Date of last notice	26 June 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr. James Graham is the trustee of the J Graham Family Trust and a beneficiary of the trust Buttonwood Nominees Pty Ltd held on behalf of Mr James Graham Bulleen Pty Ltd an entity controlled by Mr Graham
Date of change	29 September 2023

Appendix 3Y

Change of Director's Interest Notice

No. of securities held prior to change	<p>Total number of fully paid ordinary shares held prior to change: 6,531,932</p> <p>Direct Interest</p> <ol style="list-style-type: none"> 1. 262,347 fully paid ordinary shares 2. 389,712 Class B Performance Shares 3. 2,250,000 Unlisted Options <p>Indirect Interest</p> <p>Mr. James Graham <J Graham Family A/c></p> <ol style="list-style-type: none"> 4. 356,250 Class B Performance Shares <p>Buttonwood Nominees Pty Ltd</p> <ol style="list-style-type: none"> 5. 5,500,000 fully paid ordinary shares <p>Bulleen Pty Ltd</p> <ol style="list-style-type: none"> 6. 769,585 fully paid ordinary shares
Class	Fully paid ordinary shares
Number acquired	233,430 fully paid ordinary shares
Number disposed	Nil
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and estimated valuation</p>	\$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	<p>Total number of fully paid ordinary shares held after change: 6,765,362</p> <p>Direct Interest</p> <ol style="list-style-type: none"> 1. 389,712 Class B Performance Shares 2. 2,250,000 Unlisted Options <p>Indirect Interest</p> <p>Mr. James Graham <J Graham Family A/c></p> <ol style="list-style-type: none"> 3. 356,250 Class B Performance Shares <p>Buttonwood Nominees Pty Ltd</p> <ol style="list-style-type: none"> 4. 6,765,362 fully paid ordinary shares
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Participation in the Company's non-renounceable pro rata Entitlement Offer as announced by the Company on 11 September 2023</p> <p>Transfer of shares from direct holdings and entities controlled by Mr Graham however there was no change in Mr Graham's relevant interest as a result of the transfers.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Justin Ward
Date of last notice	25 February 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	29 September 2023
No. of securities held prior to change	158,966 fully paid ordinary shares 600,000 unlisted options each exercisable as \$1.56, expiring 22 February 2026
Class	Fully paid ordinary shares
Number acquired	6,114 fully paid ordinary shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	165,080 fully paid ordinary shares 600,000 unlisted options each exercisable as \$1.56, expiring 22 February 2026

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's non-renounceable pro rata Entitlement Offer as announced by the Company on 11 September 2023
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ABN	73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alistair McKeough
Date of last notice	15 November 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Finn Frist Pty Ltd as trustee for the AZM Superannuation Fund of which Mr McKeough is a director and shareholder of the trustee and a beneficiary of the trust (Finn Frist Pty Ltd) Amabel Pty Limited as trustee for the McKeough Family Trust of which Mr McKeough is a director of the trustee and a beneficiary of the trust (Amabel Pty Limited)
Date of change	29 September 2023
No. of securities held prior to change	Finn Frist Pty Ltd 1. 25,000 fully paid ordinary shares Amabel Pty Limited 2. 1,125,000 unlisted options each exercisable as \$1.56, expiring 15 November 2027
Class	Fully paid ordinary shares
Number acquired	961 fully paid ordinary shares
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.44 (44 cents) per fully paid ordinary share
No. of securities held after change	Finn Frist Pty Ltd 1. 25,961 fully paid ordinary shares Amabel Pty Limited 2. 1,125,000 unlisted options each exercisable as \$1.56, expiring 15 November 2027
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in the Company's non-renounceable pro rata Entitlement Offer as announced by the Company on 11 September 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.